ZFX and prostate carcinoma: However, less than half of the bound promoters show responsiveness to loss of ZFX and ZNF711 in the knockout HEK293T cells (Figure 3) or after knockdown of all three family members in 22Rv1 prostate cancer cells (data not shown).